Combination of | |
---|---|
Empagliflozin | SGLT2 inhibitor |
Linagliptin | DPP-4 inhibitor |
Clinical data | |
Trade names | Glyxambi |
AHFS/ Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C48H55ClN8O9 |
Molar mass | 923.47 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. [5] [6] It is a combination of empagliflozin and linagliptin. [5] [6] It is taken by mouth. [5] [6]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6]
It was approved for use in the United States in January 2015, [7] [8] for use in the European Union in November 2016, [6] and for use in Australia in December 2016. [2]
In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. [5]
In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus: [6]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels). [6]
The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi. [9]